PMID- 25184231
OWN - NLM
STAT- MEDLINE
DCOM- 20141113
LR  - 20170512
IS  - 0890-9091 (Print)
IS  - 0890-9091 (Linking)
VI  - 27 Suppl 3
DP  - 2013 Dec
TI  - Management of hematologic adverse events in patients with relapsed and/or 
      refractory multiple myeloma treated with single-agent carfilzomib.
PG  - 11-8
LID - 189773 [pii]
AB  - Hematologic adverse events (AEs) are commonly encountered in patients with 
      multiple myeloma (MM) owing to the nature of the disease and the adverse effects 
      related to myeloma treatment. Immunomodulatory drugs (eg, thalidomide, 
      lenalidomide, and pomalidomide) and the proteasome inhibitor bortezomib have all 
      been associated with increased rates of anemia, neutropenia, and 
      thrombocytopenia, as well as greater incidences of infection caused by associated 
      immunosuppression. The proteasome inhibitor carfilzomib was recently approved in 
      the United States for the treatment of patients with relapsed and refractory MM. 
      This article reviews the hematologic safety profile of carfilzomib in patients 
      with relapsed/refractory MM, as assessed in a cross-trial safety analysis of four 
      phase II studies, and makes recommendations for the appropriate management of 
      hematologic AEs.
FAU - Nooka, Ajay K
AU  - Nooka AK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Oncology (Williston Park)
JT  - Oncology (Williston Park, N.Y.)
JID - 8712059
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Oligopeptides)
RN  - 0 (Proteasome Inhibitors)
RN  - 72X6E3J5AR (carfilzomib)
SB  - IM
MH  - Anemia/chemically induced/therapy
MH  - Antibiotic Prophylaxis
MH  - Antineoplastic Agents/*adverse effects
MH  - Humans
MH  - Multiple Myeloma/*drug therapy
MH  - Neutropenia/chemically induced/therapy
MH  - Oligopeptides/*adverse effects
MH  - Proteasome Inhibitors/*adverse effects
MH  - Recurrence
MH  - Thrombocytopenia/chemically induced/therapy
EDAT- 2014/09/04 06:00
MHDA- 2014/11/14 06:00
CRDT- 2014/09/04 06:00
PHST- 2014/09/04 06:00 [entrez]
PHST- 2014/09/04 06:00 [pubmed]
PHST- 2014/11/14 06:00 [medline]
AID - 189773 [pii]
PST - ppublish
SO  - Oncology (Williston Park). 2013 Dec;27 Suppl 3:11-8.